Literature DB >> 24362682

Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.

Peter L Collins1, Rachel Fearns, Barney S Graham.   

Abstract

Human respiratory syncytial virus (RSV) is an enveloped, nonsegmented negative-strand RNA virus of family Paramyxoviridae. RSV is the most complex member of the family in terms of the number of genes and proteins. It is also relatively divergent and distinct from the prototype members of the family. In the past 30 years, we have seen a tremendous increase in our understanding of the molecular biology of RSV based on a succession of advances involving molecular cloning, reverse genetics, and detailed studies of protein function and structure. Much remains to be learned. RSV disease is complex and variable, and the host and viral factors that determine tropism and disease are poorly understood. RSV is notable for a historic vaccine failure in the 1960s involving a formalin-inactivated vaccine that primed for enhanced disease in RSV naïve recipients. Live vaccine candidates have been shown to be free of this complication. However, development of subunit or other protein-based vaccines for pediatric use is hampered by the possibility of enhanced disease and the difficulty of reliably demonstrating its absence in preclinical studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362682      PMCID: PMC4794264          DOI: 10.1007/978-3-642-38919-1_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  131 in total

1.  The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.

Authors:  Ruchira Mitra; Pradyumna Baviskar; Rebecca R Duncan-Decocq; Darshna Patel; Antonius G P Oomens
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Evaluation of pneumonia virus of mice as a possible human pathogen.

Authors:  Linda G Brock; Ruth A Karron; Christine D Krempl; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract.

Authors:  Peter F Wright; Mine R Ikizler; Ricardo A Gonzales; Kecia N Carroll; Joyce E Johnson; Jay A Werkhaven
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.

Authors:  Fernando P Polack; Pablo M Irusta; Scott J Hoffman; M Paula Schiatti; Guillermina A Melendi; M Florencia Delgado; Federico R Laham; Bhagvanji Thumar; R Michael Hendry; Jose A Melero; Ruth A Karron; Peter L Collins; Steven R Kleeberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-14       Impact factor: 11.205

6.  Evidence that the respiratory syncytial virus polymerase complex associates with lipid rafts in virus-infected cells: a proteomic analysis.

Authors:  Terence P McDonald; Andrew R Pitt; Gaie Brown; Helen W McL Rixon; Richard J Sugrue
Journal:  Virology       Date:  2004-12-05       Impact factor: 3.616

7.  Function of the respiratory syncytial virus small hydrophobic protein.

Authors:  Sandra Fuentes; Kim C Tran; Priya Luthra; Michael N Teng; Biao He
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

8.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

9.  Sorting of the respiratory syncytial virus matrix protein into detergent-resistant structures is dependent on cell-surface expression of the glycoproteins.

Authors:  Gary Henderson; Jillian Murray; Robert P Yeo
Journal:  Virology       Date:  2002-09-01       Impact factor: 3.616

10.  RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.

Authors:  H Grosfeld; M G Hill; P L Collins
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  94 in total

1.  Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

Authors:  Jeremy R Duvall; Lynn VerPlank; Barbara Ludeke; Sarah M McLeod; Maurice D Lee; Karthick Vishwanathan; Carol A Mulrooney; Sebastian Le Quement; Qin Yu; Michelle A Palmer; Paul Fleming; Rachel Fearns; Michael A Foley; Christina A Scherer
Journal:  Antiviral Res       Date:  2016-04-06       Impact factor: 5.970

2.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter.

Authors:  Sarah L Noton; Kartikeya Nagendra; Ewan F Dunn; Michael E Mawhorter; Qin Yu; Rachel Fearns
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 3.  Initiation and regulation of paramyxovirus transcription and replication.

Authors:  Sarah L Noton; Rachel Fearns
Journal:  Virology       Date:  2015-02-13       Impact factor: 3.616

4.  T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Authors:  D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

5.  Mechanism of action for respiratory syncytial virus inhibitor RSV604.

Authors:  SreeRupa Challa; Andrew D Scott; Olga Yuzhakov; Ying Zhou; Choi Lai Tiong-Yip; Ning Gao; Jason Thresher; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

Review 6.  Novel antigens for RSV vaccines.

Authors:  Barney S Graham; Kayvon Modjarrad; Jason S McLellan
Journal:  Curr Opin Immunol       Date:  2015-06-10       Impact factor: 7.486

Review 7.  Neutralizing epitopes of RSV and palivizumab resistance in Japan.

Authors:  Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2017-09-01

8.  Characterization of a respiratory syncytial virus L protein inhibitor.

Authors:  Choi-Lai Tiong-Yip; Lisa Aschenbrenner; Kenneth D Johnson; Robert E McLaughlin; Jun Fan; SreeRupa Challa; Hui Xiong; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

9.  Differential Responses by Human Respiratory Epithelial Cell Lines to Respiratory Syncytial Virus Reflect Distinct Patterns of Infection Control.

Authors:  Philippa Hillyer; Rachel Shepard; Megan Uehling; Mina Krenz; Faruk Sheikh; Kalyn R Thayer; Lei Huang; Lihan Yan; Debasis Panda; Cindy Luongo; Ursula J Buchholz; Peter L Collins; Raymond P Donnelly; Ronald L Rabin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

10.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.